跳转至内容
Merck
CN

SML2485

Sigma-Aldrich

麻保沙星

≥98% (HPLC)

别名:

9-氟代-2,3-二氢-3-甲基-10-(4-甲基-哌嗪)-7-氧代-7H-吡啶并[1,2,3-ij][1,2,4]苯并噁二嗪-6-羧酸, Zeniquin®

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C17H19FN4O4
分子量:
362.36
MDL编号:
UNSPSC代码:
12352200
NACRES:
NA.77

方案

≥98% (HPLC)

表单

powder

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear (warmed)

储存温度

2-8°C

SMILES字符串

CN1CCN(CC1)c2c(F)cc3C(=O)C(=CN4N(C)COc2c34)C(O)=O

InChI

1S/C17H19FN4O4/c1-19-3-5-21(6-4-19)14-12(18)7-10-13-16(14)26-9-20(2)22(13)8-11(15(10)23)17(24)25/h7-8H,3-6,9H2,1-2H3,(H,24,25)

InChI key

BPFYOAJNDMUVBL-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

生化/生理作用

Marbofloxacin is a broad-spectrum fluoroquinolone antibiotic active against both Gram-negative and Gram-positive bacteria. It is believed to act by impairing the bacterial DNA gyrase. Marbofloxacin has also been shown to exhibit antileishmanial activity in a canine model.

法律信息

Zeniquin is a registered trademark of Pfizer, Inc.

危险声明

预防措施声明

危险分类

Aquatic Chronic 3

储存分类代码

11 - Combustible Solids

WGK

WGK 2

法规信息

新产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

M Spreng et al.
Journal of veterinary pharmacology and therapeutics, 18(4), 284-289 (1995-08-01)
Marbofloxacin is a new fluoroquinolone developed exclusively for veterinary use. Minimum inhibitory concentrations of marbofloxacin were assessed for 816 recent isolates associated with canine or feline diseases. Marbofloxacin showed a broad spectrum of activity against gram-negative and gram-positive bacteria. In
Carmen Pineda et al.
PloS one, 12(10), e0185981-e0185981 (2017-10-06)
Treatment of canine leishmaniasis (CanL) represents a challenge. Due to the high prevalence of renal disease associated to CanL, it is important to find an effective drug that does not damage the kidneys. Marbofloxacin has been shown to be effective
Marilisa Novacco et al.
Veterinary microbiology, 217, 112-120 (2018-04-05)
Mycoplasma haemofelis is the most pathogenic feline hemoplasma species and a causative agent of infectious hemolytic anemia in cats. Current treatment protocols are effective in reducing M. haemofelis blood loads and clinical signs but consistent bacteremia clearance is rarely achieved.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门